SOPHiA GENETICS Future Growth
Future criteria checks 2/6
SOPHiA GENETICS is forecast to grow earnings and revenue by 21.7% and 21.8% per annum respectively. EPS is expected to grow by 23.5% per annum. Return on equity is forecast to be -76.4% in 3 years.
Key information
21.7%
Earnings growth rate
23.5%
EPS growth rate
| Healthcare Services earnings growth | 27.4% |
| Revenue growth rate | 21.8% |
| Future return on equity | -76.4% |
| Analyst coverage | Low |
| Last updated | 08 Apr 2024 |
Recent future growth updates
Recent updates
SOPHiA GENETICS SA (NASDAQ:SOPH) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mar 09
Sophia Genetics: Breakthrough Potential In A Cautious Healthcare Sector
Feb 12Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Dec 27Why Investors Shouldn't Be Surprised By SOPHiA GENETICS SA's (NASDAQ:SOPH) 35% Share Price Surge
Nov 09Is SOPHiA GENETICS (NASDAQ:SOPH) In A Good Position To Invest In Growth?
Aug 08Here's Why We're Watching SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Dec 15SOPHiA GENETICS partnering with Boundless Bio on oncogene cancer therapies
Sep 21SOPHiA Genetics GAAP EPS of -$0.39 in-line, revenue of $11.7M misses by $0.25M
Aug 09We're Hopeful That SOPHiA GENETICS (NASDAQ:SOPH) Will Use Its Cash Wisely
Jul 01SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 18We Think SOPHiA GENETICS (NASDAQ:SOPH) Can Afford To Drive Business Growth
Mar 10Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Nov 24Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 129 | -45 | N/A | -9 | 3 |
| 12/31/2025 | 101 | -53 | N/A | -25 | 4 |
| 12/31/2024 | 79 | -66 | N/A | -36 | 4 |
| 12/31/2023 | 62 | -79 | -58 | -49 | N/A |
| 9/30/2023 | 59 | -69 | -58 | -48 | N/A |
| 6/30/2023 | 54 | -78 | -68 | -58 | N/A |
| 3/31/2023 | 51 | -82 | -77 | -67 | N/A |
| 12/31/2022 | 48 | -87 | -80 | -70 | N/A |
| 9/30/2022 | 45 | -95 | -84 | -75 | N/A |
| 6/30/2022 | 44 | -93 | -77 | -69 | N/A |
| 3/31/2022 | 42 | -86 | -73 | -65 | N/A |
| 12/31/2021 | 40 | -74 | -65 | -58 | N/A |
| 9/30/2021 | 37 | -63 | -58 | -52 | N/A |
| 6/30/2021 | 34 | -52 | -51 | -46 | N/A |
| 3/31/2021 | 30 | -41 | -39 | -35 | N/A |
| 12/31/2020 | 28 | -39 | -35 | -32 | N/A |
| 12/31/2019 | 25 | -34 | -35 | -32 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SOPH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SOPH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SOPH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SOPH's revenue (21.8% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: SOPH's revenue (21.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SOPH is forecast to be unprofitable in 3 years.